Submitted: 21 Apr 2024
Accepted: 08 Jun 2024
ePublished: 24 Jun 2024
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Nephropharmacol. 2024;13(2): e12686.
doi: 10.34172/npj.2024.12686
  Abstract View: 135
  PDF Download: 63


Prognosis and factors affecting mortality in patients with acute kidney injury due to cardiorenal syndrome type 1 treated with sustained low-efficiency dialysis

Thanapon Nilmoje ORCID logo, Dhipsukon Pongborriboon, Ussanee Boonsrirat, Sirihatai Konwai, Suntornwit Praditau-Krit, Atthaphong Phongphithakchai* ORCID logo

1 Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand
*Corresponding Author: Atthaphong Phongphithakchai, Email: patthaph@medicine.psu.ac.th, Email: ton331@hotmail.com


Introduction: Cardiorenal syndrome (CRS) type 1 is linked to poor outcomes, particularly in-hospital mortality. While diuretics are commonly used, their efficacy may be limited necessitating renal replacement therapy (RRT) often using continuous renal replacement therapy (CRRT). However, the cost and availability limit CRRT usage, prompting exploration of alternative therapies like sustained low efficiency dialysis (SLED).

Objectives: We conducted a retrospective analysis to explore significant factors affecting mortality rates in CRS type 1 patients treated with SLED.

Patients and Methods: This is a retrospective cohort study conducted in a tertiary hospital from 2012 to 2022, including 215 CRS type 1 patients treated with SLED. The patients were categorized into the survivors’ group and the nonsurvivors’ group. The clinical indicators and biochemical markers for each group were compared to identify any disparities. Additionally, multivariate logistic regression analysis was conducted to ascertain the independent risk factors.

Results: The in-hospital mortality was 49.3%. Hydralazine administration prior to admission (odd ratio [OR]: 0.39, 95% CI 0.18–0.86) serum creatinine at SLED initiation (OR: 0.86, 95% CI 0.77–0.96), intra-aortic balloon pumps (IABP) treatment (OR: 2.04, 95% CI 1.28–3.26), and urine output <400 mL/d in 24 hours prior discontinuing SLED (OR: 3.61, 95% CI 2.01–6.49) were associated with increased risk of in-hospital mortality.

Conclusion: SLED-based RRT for acute kidney injury in type 1 CRS is linked to higher in-hospital mortality for patients not previously administered hydralazine, having low serum creatinine, IABP usage, and experiencing oliguria.

Implication for health policy/practice/research/medical education:

Incorporating assessments of pre-admission hydralazine administration, serum creatinine levels, intra-aortic balloon pump treatment, and oliguria into clinical guidelines may significantly enhance management strategies for cardiorenal syndrome type 1 patients treated with sustained low-efficiency dialysis.

Please cite this paper as: Nilmoje T, Pongborriboon D, Boonsrirat U, Konwai S, Praditau-Krit S, Phongphithakchai A. Prognosis and factors affecting mortality in patients with acute kidney injury due to cardiorenal syndrome type 1 treated with sustained low-efficiency dialysis. J Nephropharmacol. 2024;13(2):e12686. DOI: 10.34172/npj.2024.12686.

First Name
Last Name
Email Address
Security code

Abstract View: 136

Your browser does not support the canvas element.

PDF Download: 63

Your browser does not support the canvas element.